Management of Mitral Valve Replacement with Bioprosthesis and LAA Clip Ligation

Immediate Postoperative Anticoagulation Strategy

The European Society of Cardiology recommends initiating anticoagulation early postoperatively using intravenous unfractionated heparin with aPTT monitoring to 1.5-2.0 times control until therapeutic INR is achieved with warfarin (target INR 2.0-3.0) 1
The American College of Cardiology suggests that if low molecular weight heparin is used instead, anti-factor Xa monitoring is essential, especially in patients with renal dysfunction or obesity where dosing is challenging 1
Oral warfarin should be begun within 24-48 hours postoperatively, overlapping with heparin until INR is therapeutic for 2 consecutive days 1

The European Society of Cardiology recommends that all patients with bioprosthetic MVR require warfarin anticoagulation for a minimum of 3 months postoperatively (INR 2.0-3.0), regardless of whether LAA ligation was performed 1, 2, 4
The American College of Cardiology suggests that if atrial fibrillation is present, continue lifelong anticoagulation with warfarin (INR 2.0-3.0) 1, 4
The American College of Cardiology notes that the LAA clip ligation does NOT eliminate the need for anticoagulation in AF patients, as incomplete occlusion occurs in approximately 50% of cases and thrombus can form elsewhere in the left atrium 5, 2

The American College of Cardiology recommends baseline transthoracic echocardiography should be performed before hospital discharge to establish a reference for future comparisons and assess bioprosthetic valve function and gradients 4
The European Society of Cardiology suggests follow-up echocardiography at 3 months to reassess valve function, detect new-onset or recurrent AF, and guide anticoagulation decisions 1
The European Society of Cardiology recommends INR monitoring, checking INR every 2-3 days initially until stable therapeutic range achieved, then weekly for 1 month, then monthly if consistently therapeutic, with a target INR 2.0-3.0 for bioprosthetic MVR 1

The European Society of Cardiology notes that structural valve deterioration typically begins 7-10 years postoperatively (earlier in younger patients) 1
The American College of Cardiology recommends annual echocardiographic surveillance starting at 5 years post-implantation to detect early degeneration 6